Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Perspective Therapeutics' pipeline led by VMT-a-NET shows early potential, but adoption risks remain despite solid cash ...

Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Clearway ...

Q2 2025 Earnings Call Transcript August 6, 2025 Fortrea Holdings Inc. beats earnings expectations. Reported EPS is $0.19, ...

Net loss (GAAP) increased by $5,600,000 to $16,600,000 for the fiscal third quarter ended June 30, 2025, reflecting a ...

THE Philippine Council for Health Research and Development (PCHRD) is seeking stronger alignment between health research and policymaking as it hosts the 18th Philippine National Health Research ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding sharehol ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.